Effect of Azilsartan on Aldosterone in Postmenopausal Females
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Azilsartan medoximil
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Post Menopause, Female, Obese
Eligibility Criteria
Inclusion Criteria:
- Female
- Ages 45-70
- Post-menopause: have not had a menstrual period for one year or more
- Diagnosed with Stage 1 hypertension
- Body Mass Index (BMI) greater than or equal to 28
Exclusion Criteria:
- Male
- Diagnosed with Stage 2 hypertension
- Stage 1 hypertension requiring more than one agent
- Pregnancy or attempting pregnancy
- Use of oral contraceptive pills
- Use of hormone replacement therapy
- Use of steroids
- Stage 3 or greater kidney disease
- Diabetes mellitus
- untreated hypothyroidism or hyperthyroidism
- primary hyperaldosteronism
- Cushing's disease
- obstructive sleep apnea
- chronic illness, e.g. chronic liver disease
- NYHA class III or greater heart failure
- moderate to severe lung disease
Sites / Locations
- University of Chicago
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
azilsartan medoximil.
Placebo
Arm Description
Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day.
Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day
Outcomes
Primary Outcome Measures
24-hour BP (Systolic)
To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on blood pressure in postmenopausal females.
24-hour BP (Diastolic)
To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on blood pressure in postmenopausal females.
Secondary Outcome Measures
Difference in 24-hour Urine Aldosterone Change From Baseline
To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on urinary aldosterone levels in postmenopausal females
Full Information
NCT ID
NCT01774591
First Posted
January 22, 2013
Last Updated
October 10, 2017
Sponsor
University of Chicago
Collaborators
Takeda
1. Study Identification
Unique Protocol Identification Number
NCT01774591
Brief Title
Effect of Azilsartan on Aldosterone in Postmenopausal Females
Official Title
Effect of Azilsartan on Aldosterone in Postmenopausal Females
Study Type
Interventional
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
January 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Chicago
Collaborators
Takeda
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the research is to evaluate the effect of azilsartan medoximil on blood pressure and urinary aldosterone levels in postmenopausal females.
Detailed Description
The study is a randomized, placebo-controlled trial of post-menopausal females with stage 1 hypertension. The goal is to randomize 40 post-menopausal females with stage 1 hypertension and assess whether azilsartan reduces urinary aldosterone levels. We will compare subjects having azilsartan medoximil (treatment group) with placebo group. Additionally, a small sub-study comparing pre-menopausal and post-menopausal female aldosterone levels was performed as well as the presence of aldosterone production in fat cell cultures of a subset of 3 patients in the randomized trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Post Menopause, Female, Obese
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
azilsartan medoximil.
Arm Type
Active Comparator
Arm Description
Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day
Intervention Type
Drug
Intervention Name(s)
Azilsartan medoximil
Other Intervention Name(s)
Edarbi
Intervention Description
All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
Primary Outcome Measure Information:
Title
24-hour BP (Systolic)
Description
To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on blood pressure in postmenopausal females.
Time Frame
26 weeks
Title
24-hour BP (Diastolic)
Description
To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on blood pressure in postmenopausal females.
Time Frame
26 weeks
Secondary Outcome Measure Information:
Title
Difference in 24-hour Urine Aldosterone Change From Baseline
Description
To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on urinary aldosterone levels in postmenopausal females
Time Frame
26 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female
Ages 45-70
Post-menopause: have not had a menstrual period for one year or more
Diagnosed with Stage 1 hypertension
Body Mass Index (BMI) greater than or equal to 28
Exclusion Criteria:
Male
Diagnosed with Stage 2 hypertension
Stage 1 hypertension requiring more than one agent
Pregnancy or attempting pregnancy
Use of oral contraceptive pills
Use of hormone replacement therapy
Use of steroids
Stage 3 or greater kidney disease
Diabetes mellitus
untreated hypothyroidism or hyperthyroidism
primary hyperaldosteronism
Cushing's disease
obstructive sleep apnea
chronic illness, e.g. chronic liver disease
NYHA class III or greater heart failure
moderate to severe lung disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
George Bakris, MD
Organizational Affiliation
University of Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Effect of Azilsartan on Aldosterone in Postmenopausal Females
We'll reach out to this number within 24 hrs